The role of minimal residual disease and serum free light chain ratio in the management of multiple myeloma

被引：0
|
作者：
Zhu, Long-Ying [1 ,2 ]
Hu, Qi-Lei [2 ]
Zhang, Liang [2 ]
Li, Zuo-Jie [3 ]
机构：
[1] Zhejiang Chinese Med Univ, Sch Med Technol & Informat Engn, Hangzhou 310053, Zhejiang, Peoples R China
[2] First Peoples Hosp Linping Dist, Dept Clin Lab, Hangzhou 311100, Zhejiang, Peoples R China
[3] Peoples Hosp Cangnan Zhejiang, Dept Clin Lab, 2288 Yucang Rd, Wenzhou 325800, Zhejiang, Peoples R China
来源：
DISCOVER ONCOLOGY | 2024年 / 15卷 / 01期
关键词：
Duration of Response (DOR); Minimal residual disease (MRD); Multiple myeloma (MM); Serum free light chain ratio (sFLCR); Stringent complete response (sCR); DEXAMETHASONE; DIAGNOSIS; SFLC;
D O I：
10.1007/s12672-024-01090-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Multiple myeloma (MM) denotes a cancerous growth characterized by abnormal proliferation of plasma cells. Growing evidence suggests that the complexity in addressing MM lies in the presence of minimal residual disease (MRD) within the body. MRD assessment is becoming increasingly important for risk assessment in patients with MM. Similarly, the levels of serum free protein light chain and their ratio play a crucial role in assessing the disease burden and changes in MM. In this paper, we review and explore the utilization of MRD and serum free light chain ratio in the treatment of MM, delving into their respective characteristics, advantages, disadvantages, and their interrelation.
引用
收藏
页数：8
相关论文
共 50 条
  • [1] Multicentered patient-based evidence of the role of free light chain ratio normalization in multiple myeloma disease relapse
    Radocha, Jakub
    Pour, Ludek
    Pika, Tomas
    Maisnar, Vladimir
    Spicka, Ivan
    Gregora, Evzen
    Krejci, Marta
    Minarik, Jiri
    Machalkova, Katerina
    Straub, Jan
    Pavlicek, Petr
    Hajek, Roman
    Zak, Pavel
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2016, 96 (02) : 119 - 127
  • [2] Role of Imaging in the Evaluation of Minimal Residual Disease in Multiple Myeloma Patients
    Zamagni, Elena
    Tacchetti, Paola
    Barbato, Simona
    Cavo, Michele
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (11) : 1 - 9
  • [3] Prognostic value of serum free light chain at diagnosis of multiple myeloma
    Phan Nguyen Thanh Van
    Cao Thi Loc
    MEDICAL SCIENCE, 2022, 26 (123)
  • [4] Determination of Minimal Residual Disease in Multiple Myeloma: Does It Matter?
    Kothari, Shalin
    Hillengass, Jens
    McCarthy, Philip L.
    Holstein, Sarah A.
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2019, 14 (01) : 39 - 46
  • [5] Minimal residual disease in multiple myeloma: current status
    Ding, Hong
    Xu, Juan
    Lin, Zhimei
    Huang, Jingcao
    Wang, Fangfang
    Yang, Yan
    Cui, Yushan
    Luo, Hongmei
    Gao, Yuhan
    Zhai, Xinyu
    Pang, Weicui
    Zhang, Li
    Zheng, Yuhuan
    BIOMARKER RESEARCH, 2021, 9 (01)
  • [6] MINIMAL RESIDUAL DISEASE IN MULTIPLE MYELOMA: IMAGING TECHNIQUES
    Zamagni, E.
    Tacchetti, P.
    Pantani, L.
    Mancuso, K.
    Zannetti, B.
    Rocchi, S.
    Rizzello, I
    Caratozzolo, I
    Nanni, C.
    Fanti, S.
    Cavo, M.
    HAEMATOLOGICA, 2018, 103 : 1 - 2
  • [7] Role of serum-free light chain assay for defining response and progression in immunoglobulin secretory multiple myeloma
    Tacchetti, Paola
    Rocchi, Serena
    Zamagni, Elena
    Barbato, Simona
    Rizzello, Ilaria
    De Cicco, Gabriella
    Pantani, Lucia
    Mancuso, Katia
    Fusco, Alessio
    Dozza, Luca
    Ursi, Margherita
    Favero, Emanuele
    Terragna, Carolina
    Testoni, Nicoletta
    Cavo, Michele
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (12) : 1607 - 1615
  • [8] Serum free light chain levels and renal function at diagnosis in patients with multiple myeloma
    Yaday, Punit
    Cockwell, Paul
    Cook, Mark
    Pinney, Jennifer
    Giles, Hannah
    Aung, Yu Sandar
    Cairns, David
    Owen, Roger G.
    Davies, Faith E.
    Jackson, Graham H.
    Child, J. Anthony
    Morgan, Gareth J.
    Drayson, Mark T.
    BMC NEPHROLOGY, 2018, 19
  • [9] Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment
    Nishihori, Taiga
    Song, Jinming
    Shain, Kenneth H.
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2016, 11 (02) : 118 - 126
  • [10] Multiple Myeloma: Minimal Residual Disease Testing - Not Ready for Primetime
    Martin, Thomas
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S46 - S48
12345